Loading...

Gabriele Bergers, PhD

Title(s)ADJ PROF-FY, Neurological Surgery
SchoolSchool of Medicine
Phone415-476-6786
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences


    Collapse Research 
    Collapse Research Activities and Funding
    Inter-regulatory function of immune-modulation and angiogenesis in cancer
    NIH/NCI R01CA201537Aug 1, 2016 - Jul 31, 2021
    Role: Principal Investigator
    Autophagy as a microenvironmental regulator of tumorigenesis and resistance
    NIH/NCI R01CA188404Sep 1, 2014 - Aug 31, 2019
    Role: Co-Principal Investigator
    Biophysical and molecular dialogue of glioma cells and the brain microenvironment
    NIH/NCI U54CA163155Sep 26, 2011 - Jul 31, 2016
    Role: Principal Investigator
    Multipotential mesenchymal stem cell-like cells in pancreatic tumorigenesis
    NIH/NCI R01CA154383Apr 1, 2011 - Mar 31, 2016
    Role: Principal Investigator
    Perivascular Invasion of GBMs
    NIH/NCI R01CA113382Aug 15, 2006 - May 31, 2011
    Role: Principal Investigator
    PDGFRbeta+-Perivascular Cells In Tumor Angiogenesis
    NIH/NCI R01CA109390Aug 1, 2004 - Jul 31, 2009
    Role: Principal Investigator
    Mechanism and therapeutic targeting of evasive resistance to antiangiogenic drugs
    NIH/NCI R01CA099948Feb 11, 2003 - May 31, 2013
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Hua Y, Bergers G. Tumors vs. Chronic Wounds: An Immune Cell's Perspective. Front Immunol. 2019; 10:2178. PMID: 31572387.
      View in: PubMed
    2. Säälik P, Lingasamy P, Toome K, Mastandrea I, Rousso-Noori L, Tobi A, Simón-Gracia L, Hunt H, Paiste P, Kotamraju VR, Bergers G, Asser T, Rätsep T, Ruoslahti E, Bjerkvig R, Friedmann-Morvinski D, Teesalu T. Peptide-guided nanoparticles for glioblastoma targeting. J Control Release. 2019 Aug 28; 308:109-118. PMID: 31255690.
      View in: PubMed
    3. Wei Wang, Stefan Grossauer, Katharina Koeck, Erin Simonds, Edbert Lu, Gabriele Bergers, William Weiss, Claudia Petritsch. TMOD-03. GAINING A MECHANISTIC UNDERSTANDING OF THERAPY EVASION FROM DUAL MAPK PATHWAY INHIBITION IN A SYNGENEIC BRAFV600E MUTANT CDKN2A DELETED MOUSE MODEL TO PREEMPT RESISTANCE IN PATIENTS WITH BRAFV600E MUTANT PEDIATRIC GLIOMA. Neuro-Oncology. 2019 Apr 23; 21(Supplement_2):ii121-ii122.
      View in: Publisher Site
    4. Mazzone M, Bergers G. Regulation of Blood and Lymphatic Vessels by Immune Cells in Tumors and Metastasis. Annu Rev Physiol. 2019 Feb 10; 81:535-560. PMID: 30742781.
      View in: PubMed
    5. Vella G, Bergers G. Where Have All the T Cells Gone? Immunity. 2018 10 16; 49(4):592-594. PMID: 30332627.
      View in: PubMed
    6. Barnes JM, Kaushik S, Bainer RO, Sa JK, Woods EC, Kai F, Przybyla L, Lee M, Lee HW, Tung JC, Maller O, Barrett AS, Lu KV, Lakins JN, Hansen KC, Obernier K, Alvarez-Buylla A, Bergers G, Phillips JJ, Nam DH, Bertozzi CR, Weaver VM. A tension-mediated glycocalyx-integrin feedback loop promotes mesenchymal-like glioblastoma. Nat Cell Biol. 2018 10; 20(10):1203-1214. PMID: 30202050.
      View in: PubMed
    7. Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018 08; 21(3):425-532. PMID: 29766399.
      View in: PubMed
    8. Missiaen R, Mazzone M, Bergers G. The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer. Semin Cancer Biol. 2018 10; 52(Pt 2):107-116. PMID: 29935312.
      View in: PubMed
    9. He B, Jabouille A, Steri V, Johansson-Percival A, Michael IP, Kotamraju VR, Junckerstorff R, Nowak AK, Hamzah J, Lee G, Bergers G, Ganss R. Vascular targeting of LIGHT normalizes blood vessels in primary brain cancer and induces intratumoural high endothelial venules. J Pathol. 2018 06; 245(2):209-221. PMID: 29603739.
      View in: PubMed
    10. Arman Jahangiri, Maxim Sidorov, Alan Nguyen, Garima Yagnik, Sung Won Han, Smita Mascharak, Michael De Lay, Jeffrey Wagner, Brandyn Castro, Brandon Imber, Kan Lu, Gabriele Bergers, William Weiss, Manish K Aghi. ANGI-12. IDENTIFICATION OF A NOVEL TYROSINE KINASE/INTEGRIN COMPLEX THAT DRIVES BRAIN METASTASES. Neuro-Oncology. 2017 Nov 6; 19(suppl_6):vi24-vi24.
      View in: Publisher Site
    11. Allen E, Missiaen R, Bergers G. Therapeutic induction of high endothelial venules (HEVs) to enhance T-cell infiltration in tumors. Oncotarget. 2017 Nov 21; 8(59):99207-99208. PMID: 29245888.
      View in: PubMed
    12. Jahangiri A, Nguyen A, Chandra A, Sidorov MK, Yagnik G, Rick J, Han SW, Chen W, Flanigan PM, Schneidman-Duhovny D, Mascharak S, De Lay M, Imber B, Park CC, Matsumoto K, Lu K, Bergers G, Sali A, Weiss WA, Aghi MK. Cross-activating c-Met/ß1 integrin complex drives metastasis and invasive resistance in cancer. Proc Natl Acad Sci U S A. 2017 10 10; 114(41):E8685-E8694. PMID: 28973887.
      View in: PubMed
    13. Allen E, Jabouille A, Rivera LB, Lodewijckx I, Missiaen R, Steri V, Feyen K, Tawney J, Hanahan D, Michael IP, Bergers G. Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. Sci Transl Med. 2017 04 12; 9(385). PMID: 28404866.
      View in: PubMed
    14. Allen E, Missiaen R, Bergers G. Trimming the Vascular Tree in Tumors: Metabolic and Immune Adaptations. Cold Spring Harb Symp Quant Biol. 2016; 81:21-29. PMID: 28396525.
      View in: PubMed
    15. Arman Jahangiri, Maxim Sidorov, Sung Won Han, William Chen, Jonathan Rick, Dina Schneidman-Duhovny, Smita Mascharak, Michael De Lay, Jeffrey Wagner, Brandyn Castro, Brandon Imber, Patrick Flanigan, Ruby Kuang, Kan Lu, Gabriele Bergers, Andrej Sali, William Weiss, Manish Aghi. DRES-11. A CROSS-ACTIVATING c-Met/ß1 INTEGRIN COMPLEX DRIVES THERAPEUTIC RESISTANCE IN GLIOBLASTOMA. Neuro-Oncology. 2016 Nov 1; 18(suppl_6):vi53-vi54.
      View in: Publisher Site
    16. Hambardzumyan D, Bergers G. Glioblastoma: Defining Tumor Niches. Trends Cancer. 2015 Dec; 1(4):252-265. PMID: 27088132.
      View in: PubMed
    17. Kan Lu, Dolores Hambardzumyan, Gabriele Bergers. CBIO-05UNDERSTANDING AND TACKLING PARACRINE SIGNALING CUES BETWEEN GLIOMA AND IMMUNE CELLS TO THWART GLIOMA INVASIVENESS AND ANGIOGENESIS. Neuro-Oncology. 2015 Nov 1; 17(suppl_5):v55-v56.
      View in: Publisher Site
    18. Rivera LB, Bergers G. CANCER. Tumor angiogenesis, from foe to friend. Science. 2015 Aug 14; 349(6249):694-5. PMID: 26273044.
      View in: PubMed
    19. Rivera LB, Meyronet D, Hervieu V, Frederick MJ, Bergsland E, Bergers G. Intratumoral myeloid cells regulate responsiveness and resistance to antiangiogenic therapy. Cell Rep. 2015 Apr 28; 11(4):577-91. PMID: 25892230.
      View in: PubMed
    20. Rivera LB, Bergers G. Intertwined regulation of angiogenesis and immunity by myeloid cells. Trends Immunol. 2015 Apr; 36(4):240-9. PMID: 25770923.
      View in: PubMed
    21. Wang AS, Lodi A, Rivera LB, Izquierdo-Garcia JL, Firpo MA, Mulvihill SJ, Tempero MA, Bergers G, Ronen SM. HR-MAS MRS of the pancreas reveals reduced lipid and elevated lactate and taurine associated with early pancreatic cancer. NMR Biomed. 2014 Nov; 27(11):1361-70. PMID: 25199993.
      View in: PubMed
    22. Gabriele Bergers, Kan Lu, Lee Rivera. UNDERSTANDING AND TACKLING THE TUMOR-IMMUNE CELL DIALOGUE DURING PROGRESSION AND THERAPEUTIC RESISTANCE. Neuro-Oncology. 2014 Jul 1; 16(suppl_3):iii16-iii16.
      View in: Publisher Site
    23. Anders I. Persson, Shirin Ilkhanizadeh, Yekaterina A. Miroshnikova, Aaron Frantz, John N. Lakins, C. David James, Tracy R. McKnight, Mitchel S. Berger, Gabriele Bergers, William A. Weiss, Valerie M. Weaver. HIGH INTERSTITIAL FLUID PRESSURE REGULATES TUMOR GROWTH AND DRUG UPTAKE IN HUMAN GLIOBLASTOMA. Neuro-Oncology. 2014 Jul 1; 16(suppl_3):iii32-iii32.
      View in: Publisher Site
    24. Rivera LB, Bergers G. Angiogenesis. Targeting vascular sprouts. Science. 2014 Jun 27; 344(6191):1449-50. PMID: 24970064.
      View in: PubMed
    25. Hyvönen M, Enbäck J, Huhtala T, Lammi J, Sihto H, Weisell J, Joensuu H, Rosenthal-Aizman K, El-Andaloussi S, Langel U, Närvänen A, Bergers G, Laakkonen P. Novel target for peptide-based imaging and treatment of brain tumors. Mol Cancer Ther. 2014 Apr; 13(4):996-1007. PMID: 24493698.
      View in: PubMed
    26. Rivera L, Pandika M, Bergers G. Escape mechanisms from antiangiogenic therapy: an immune cell's perspective. Adv Exp Med Biol. 2014; 772:83-99. PMID: 24272355.
      View in: PubMed
    27. Rivera LB, Bergers G. Location, location, location: macrophage positioning within tumors determines pro- or antitumor activity. Cancer Cell. 2013 Dec 09; 24(6):687-9. PMID: 24332035.
      View in: PubMed
    28. Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, Marshall R, Perry A, Bjorgan KM, Chaumeil MM, Ronen SM, Bergers G, Aghi MK. Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 2013 Apr 01; 19(7):1773-83. PMID: 23307858.
      View in: PubMed
    29. Lu KV, Bergers G. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol. 2013 Jan; 2(1):49-65. PMID: 23750318.
      View in: PubMed
    30. Lu KV, Chang JP, Parachoniak CA, Pandika MM, Aghi MK, Meyronet D, Isachenko N, Fouse SD, Phillips JJ, Cheresh DA, Park M, Bergers G. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell. 2012 Jul 10; 22(1):21-35. PMID: 22789536.
      View in: PubMed
    31. Sugiarto S, Persson AI, Munoz EG, Waldhuber M, Lamagna C, Andor N, Hanecker P, Ayers-Ringler J, Phillips J, Siu J, Lim DA, Vandenberg S, Stallcup W, Berger MS, Bergers G, Weiss WA, Petritsch C. Asymmetry-defective oligodendrocyte progenitors are glioma precursors. Cancer Cell. 2011 Sep 13; 20(3):328-40. PMID: 21907924.
      View in: PubMed
    32. Dvorak HF, Weaver VM, Tlsty TD, Bergers G. Tumor microenvironment and progression. J Surg Oncol. 2011 May 01; 103(6):468-74. PMID: 21480238.
      View in: PubMed
    33. Persson AI, Petritsch C, Swartling FJ, Itsara M, Sim FJ, Auvergne R, Goldenberg DD, Vandenberg SR, Nguyen KN, Yakovenko S, Ayers-Ringler J, Nishiyama A, Stallcup WB, Berger MS, Bergers G, McKnight TR, Goldman SA, Weiss WA. Non-stem cell origin for oligodendroglioma. Cancer Cell. 2010 Dec 14; 18(6):669-82. PMID: 21156288.
      View in: PubMed
    34. Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009 Sep 01; 69(17):6889-98. PMID: 19690143.
      View in: PubMed
    35. Manish Kumar Aghi, Samuel D. Rose, Scott R. VandenBerg, Gabriele Bergers. Identifying Mechanisms of Bevacizumab Evasion in Human Glioblastoma. Neurosurgery. 2009 Aug 1; 65(2):424.
      View in: Publisher Site
    36. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009 Mar 03; 15(3):220-31. PMID: 19249680.
      View in: PubMed
    37. Gabriele Bergers. Bone Marrow-Derived Cells in GBM Neovascularization. CNS Cancer. 2009 Jan 1; 749-773.
      View in: Publisher Site
    38. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer. 2008 Aug; 8(8):592-603. PMID: 18650835.
      View in: PubMed
    39. Silber J, Lim DA, Petritsch C, Persson AI, Maunakea AK, Yu M, Vandenberg SR, Ginzinger DG, James CD, Costello JF, Bergers G, Weiss WA, Alvarez-Buylla A, Hodgson JG. miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med. 2008 Jun 24; 6:14. PMID: 18577219.
      View in: PubMed
    40. Du R, Petritsch C, Lu K, Liu P, Haller A, Ganss R, Song H, Vandenberg S, Bergers G. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol. 2008 Jun; 10(3):254-64. PMID: 18359864.
      View in: PubMed
    41. Du R, Lu KV, Petritsch C, Liu P, Ganss R, Passegué E, Song H, Vandenberg S, Johnson RS, Werb Z, Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell. 2008 Mar; 13(3):206-20. PMID: 18328425.
      View in: PubMed
    42. Pietras K, Pahler J, Bergers G, Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med. 2008 Jan 29; 5(1):e19. PMID: 18232728.
      View in: PubMed
    43. Lu K, Lamagna C, Bergers G. Chapter 3. Bone marrow-derived vascular progenitors and proangiogenic monocytes in tumors. Methods Enzymol. 2008; 445:53-82. PMID: 19022055.
      View in: PubMed
    44. Gabriele Bergers. Pericytes, the Mural Cells of the Microvascular System. Angiogenesis. 2008 Jan 1; 45-53.
      View in: Publisher Site
    45. Chesler L, Goldenberg DD, Seales IT, Satchi-Fainaro R, Grimmer M, Collins R, Struett C, Nguyen KN, Kim G, Tihan T, Bao Y, Brekken RA, Bergers G, Folkman J, Weiss WA. Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma. Cancer Res. 2007 Oct 01; 67(19):9435-42. PMID: 17909053.
      View in: PubMed
    46. Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, Baker SJ, Bergers G, Pieper RO. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res. 2006 Dec 01; 66(23):11331-40. PMID: 17145879.
      View in: PubMed
    47. R. Du, C. Petritsch, H. Song, Z. Werb, G. Bergers. ID: 373 MMP-9-dependent regulation of angiogenesis and invasion in GBM. Journal of Thrombosis and Haemostasis. 2006 Oct 1; 4(s1):46-46.
      View in: Publisher Site
    48. Lamagna C, Bergers G. The bone marrow constitutes a reservoir of pericyte progenitors. J Leukoc Biol. 2006 Oct; 80(4):677-81. PMID: 16888086.
      View in: PubMed
    49. Holash J, Thurston G, Rudge JS, Yancopoulos GD, Adjei AA, Bergers G, Pytowski B, Pegram M, Gordon MS. Inhibitors of growth factor receptors, signaling pathways and angiogenesis as therapeutic molecular agents. Cancer Metastasis Rev. 2006 Jun; 25(2):243-52. PMID: 16770536.
      View in: PubMed
    50. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005 Oct; 8(4):299-309. PMID: 16226705.
      View in: PubMed
    51. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005 Oct; 7(4):452-64. PMID: 16212810.
      View in: PubMed
    52. Song S, Ewald AJ, Stallcup W, Werb Z, Bergers G. PDGFRbeta+ perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat Cell Biol. 2005 Sep; 7(9):870-9. PMID: 16113679.
      View in: PubMed
    53. Berger M, Bergers G, Arnold B, Hämmerling GJ, Ganss R. Regulator of G-protein signaling-5 induction in pericytes coincides with active vessel remodeling during neovascularization. Blood. 2005 Feb 01; 105(3):1094-101. PMID: 15459006.
      View in: PubMed
    54. Kanamori M, Vanden Berg SR, Bergers G, Berger MS, Pieper RO. Integrin beta3 overexpression suppresses tumor growth in a human model of gliomagenesis: implications for the role of beta3 overexpression in glioblastoma multiforme. Cancer Res. 2004 Apr 15; 64(8):2751-8. PMID: 15087390.
      View in: PubMed
    55. Joyce JA, Laakkonen P, Bernasconi M, Bergers G, Ruoslahti E, Hanahan D. Stage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesis. Cancer Cell. 2003 Nov; 4(5):393-403. PMID: 14667506.
      View in: PubMed
    56. Blouw B, Song H, Tihan T, Bosze J, Ferrara N, Gerber HP, Johnson RS, Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell. 2003 Aug; 4(2):133-46. PMID: 12957288.
      View in: PubMed
    57. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003 Jun; 3(6):401-10. PMID: 12778130.
      View in: PubMed
    58. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest. 2003 May; 111(9):1287-95. PMID: 12727920.
      View in: PubMed
    59. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002 May 15; 62(10):2731-5. PMID: 12019144.
      View in: PubMed